Nov 25, 2020
LivaNova to Present at the Berenberg European Conference 2020
LONDON --(BUSINESS WIRE)--Nov. 25, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, will participate in discussions at the Berenberg European Conference 2020. The discussion is scheduled to begin at 4 p.m.
Nov 23, 2020
LivaNova to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
LONDON --(BUSINESS WIRE)--Nov. 23, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, will participate in discussions at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place November 30 –
Nov 10, 2020
LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference
LONDON --(BUSINESS WIRE)--Nov. 10, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 at 10:40 a.m.
Oct 29, 2020
LivaNova Reports Third Quarter 2020 Results
Company announces Chief Financial Officer transition LONDON --(BUSINESS WIRE)--Oct. 29, 2020-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2020 . For the third quarter of 2020, worldwide sales
Oct 12, 2020
LivaNova Confirms Receipt of Letter from PrimeStone Capital
LONDON --(BUSINESS WIRE)--Oct. 12, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today confirmed receipt of a letter from PrimeStone Capital LLP (PrimeStone) to its Board of Directors and issued the following statement: “LivaNova welcomes open
Oct 12, 2020
LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve
New PERSIST-AVR study results and SURE-AVR registry data analysis underscore utility of Perceval as a minimally invasive surgical approach for patients with aortic valve stenosis LONDON --(BUSINESS WIRE)--Oct. 12, 2020-- LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation
Sep 28, 2020
LivaNova to Host Conference Call for Third Quarter 2020 Results
LONDON --(BUSINESS WIRE)--Sep. 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London time ( 8 a.m. Eastern Daylight Time ).
Sep 01, 2020
LivaNova to Present at the Baird 2020 Global Healthcare Conference
LONDON --(BUSINESS WIRE)--Sep. 1, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present at the Baird 2020 Global Healthcare Conference on Thursday, September 10 at 9:05 a.m.
Aug 12, 2020
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LONDON --(BUSINESS WIRE)--Aug. 12, 2020-- LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve
Jul 29, 2020
LivaNova Reports Second Quarter 2020 Results
LONDON --(BUSINESS WIRE)--Jul. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020 . For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million , a decrease
Jul 16, 2020
LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe
The next-generation sutureless surgical technology is based on a clinically proven platform and designed for valve durability LONDON --(BUSINESS WIRE)--Jul. 16, 2020-- LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval ®
Jul 07, 2020
LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression
LONDON --(BUSINESS WIRE)--Jul. 7, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials 1 , which details the design for “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem
Jun 29, 2020
LivaNova to Host Conference Call for Second Quarter 2020 Results
LONDON --(BUSINESS WIRE)--Jun. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m. London time ( 7 a.m. Eastern Daylight Time ).
Jun 12, 2020
LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025
LONDON --(BUSINESS WIRE)--Jun. 12, 2020-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S. subsidiary, LivaNova USA, Inc.
Jun 11, 2020
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes
LONDON --(BUSINESS WIRE)--Jun. 11, 2020-- LivaNova PLC (NASDAQ:LIVN) (" LivaNova ") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S. subsidiary, LivaNova USA, Inc.
Jun 11, 2020
LivaNova Announces New Senior Secured Credit Facility
LONDON --(BUSINESS WIRE)--Jun. 11, 2020-- LivaNova PLC (NASDAQ:LIVN) (“The Company” or “LivaNova”) today announced its entry into a five-year $450 million senior secured credit facility (the “Credit Facility”) through its wholly owned U.S. subsidiary, LivaNova USA, Inc.
Jun 01, 2020
LivaNova to Present at the Jefferies Virtual Healthcare Conference
LONDON --(BUSINESS WIRE)--Jun. 1, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern Time .
May 28, 2020
New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves
PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LONDON --(BUSINESS WIRE)--May 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus
May 20, 2020
New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression
LONDON --(BUSINESS WIRE)--May 20, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders 1 that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy ® ) to
May 19, 2020
LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting
LONDON --(BUSINESS WIRE)--May 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval ® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at the 100 th Annual Meeting of the
May 11, 2020
LivaNova to Present at the UBS Virtual Global Healthcare Conference
LONDON --(BUSINESS WIRE)--May 11, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time .
Apr 29, 2020
LivaNova Reports First Quarter 2020 Results
LONDON --(BUSINESS WIRE)--Apr. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020 . For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million , a decrease
Apr 27, 2020
LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON --(BUSINESS WIRE)--Apr. 27, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned
Apr 22, 2020
LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
Various products can now be used to treat patients experiencing acute respiratory or cardiopulmonary failure LONDON --(BUSINESS WIRE)--Apr. 22, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products
Mar 30, 2020
LivaNova to Host Conference Call for First Quarter 2020 Results
LONDON --(BUSINESS WIRE)--Mar. 30, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time ).
Mar 26, 2020
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LONDON --(BUSINESS WIRE)--Mar. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of
Mar 09, 2020
LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression
Two UK patients receive innovative VNS Therapy implantable device through new pathway LONDON --(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System, Symmetry™, earned CE
Feb 26, 2020
LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression
RECOVER sub-study will leverage Verily research tools to provide quantitative assessment measures of depressive episodes LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with
Feb 26, 2020
LivaNova Reports Fourth Quarter and Full-Year 2019 Results
LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019 . For the fourth quarter of 2019, worldwide sales were $287.6 million , a decrease of 3.2
Feb 25, 2020
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler ® devices.
Feb 19, 2020
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LONDON --(BUSINESS WIRE)--Feb. 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for
Jan 28, 2020
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results
LONDON --(BUSINESS WIRE)--Jan. 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26, 2020 at 1 p.m. London time ( 8 a.m. Eastern Standard Time ).
